Heptares Therapeutics will receive a milestone payment from partner Teva Pharmaceutical Industries (NYSE: TEVA), as the Israeli company advances the two firms’ migraine therapy candidate into further preclinical studies.
Heptares is a subsidiary of Japanese drugmaker Sosei Group (TYO Mothers Index: 4565).
The small molecule, which was discovered using Heptares’ “structure-based” drug discovery platform is a calcitonin gene-related peptide (CGRP) antagonist.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze